Geneos Wealth Management’s Interpublic Group of Companies IPG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-2,327
Closed -$57K 2828
2025
Q2
$57K Buy
2,327
+60
+3% +$1.46K ﹤0.01% 1498
2025
Q1
$61.6K Sell
2,267
-992
-30% -$27.2K ﹤0.01% 1376
2024
Q4
$91.3K Sell
3,259
-40
-1% -$1.19K ﹤0.01% 1101
2024
Q3
$104K Buy
+3,299
New +$101K ﹤0.01% 952
2023
Q4
Sell
-750
Closed -$21.5K 2135
2023
Q3
$21.5K Buy
+750
New +$25K ﹤0.01% 1351
2022
Q2
Sell
-47
Closed -$1K 2686
2022
Q1
$1K Sell
47
-128
-73% -$4.61K ﹤0.01% 2655
2021
Q4
$6K Buy
+175
New +$6.36K ﹤0.01% 2350
2021
Q2
Sell
-1,353
Closed -$42K 2985
2021
Q1
$42K Buy
+1,353
New +$35.7K ﹤0.01% 1718
2020
Q1
Sell
-1,608
Closed -$37K 2546
2019
Q4
$37K Buy
1,608
+65
+4% +$1.43K ﹤0.01% 1409
2019
Q3
$33K Buy
1,543
+903
+141% +$19.5K ﹤0.01% 1374
2019
Q2
$14K Buy
+640
New +$14.2K ﹤0.01% 1782
2017
Q3
Sell
-95
Closed -$2K 2129
2017
Q2
$2K Buy
+95
New +$2.32K ﹤0.01% 1933

Other funds holding IPG

Geneos Wealth Management's IPG Position: Q3 2025 in Review

Geneos Wealth Management sold out of Interpublic Group of Companies (IPG) in Q3 2025, closing a stake of 2,327 shares — an estimated $57K sold.

Geneos Wealth Management first reported a position in IPG in Q2 2017 and held it in 12 quarters. The position peaked at $104K in Q3 2024. 640 funds tracked by Wall St. Rank hold IPG as of Q3 2025.

  • Geneos Wealth Management reported no remaining Interpublic Group of Companies position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 2,327 Interpublic Group of Companies shares in Q3 2025, an estimated $57K.
  • Geneos Wealth Management first reported a position in Interpublic Group of Companies in Q2 2017 and held it in 12 quarters.
  • Geneos Wealth Management's Interpublic Group of Companies position peaked at $104K in Q3 2024.
  • 640 funds tracked by Wall St. Rank held Interpublic Group of Companies as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.